Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    savita thakur thakur
    savita thakur thakur
      • Home
      • savita thakur thakur

      Articles By : savita thakur thakur

      Lupin gets USFDA nod for potassium deficiency treatment drug

      Lupin gets USFDA nod for potassium deficiency treatment drug

      savita thakur thakur13 Aug 2016 9:35 AM IST
      Pharma major Lupin’s US arm Gavis Pharmaceuticals LLC has received final approval from the USFDA for its generic version of Upsher-Smith Labs’...
      Japanese companies eye healthcare sector in India

      Japanese companies eye healthcare sector in India

      savita thakur thakur12 Aug 2016 2:20 PM IST
      New Delhi : Aiming at the huge potential that the healthcare sector in India possesses, two Japanese companies have joined hands with medical chain...
      AstraZeneca bets another $140 million on Moderna

      AstraZeneca bets another $140 million on Moderna's messenger drugs

      savita thakur thakur12 Aug 2016 2:18 PM IST
      AstraZeneca has invested another $140 million in Moderna Therapeutics, the U.S. biotech "unicorn" which already has a cash pile of around $1 billion...
      CCI rejects complaint against Safdarjung hospital, HSCC India

      CCI rejects complaint against Safdarjung hospital, HSCC India

      savita thakur thakur12 Aug 2016 2:18 PM IST
      New Delhi : Competition Commission dismissed allegations of unfair business practices against government-owned HSCC India with regard to certain...
      Suven Life Sciences Q1 net up 58.1% at Rs 32.57 cr

      Suven Life Sciences Q1 net up 58.1% at Rs 32.57 cr

      savita thakur thakur12 Aug 2016 2:17 PM IST
      Suven Life Sciences reported a 58.1 percent increase in net profit to Rs 32.57 crore for the first quarter ended June 30, 2016.The company had posted...
      Enquire Patanjalis Putrajeevak Vati: Centre tells Uttarakhand

      Enquire Patanjalis Putrajeevak Vati: Centre tells Uttarakhand

      savita thakur thakur11 Aug 2016 1:48 PM IST
      The Centre has asked the Uttarakhand government to “enquire” into the issues surrounding Patanjali Ayurveda’s controversial ‘Putrajeevak Vati’...
      Morepen Labs Strengthens Position in Bulk Drugs Market

      Morepen Labs Strengthens Position in Bulk Drugs Market

      savita thakur thakur11 Aug 2016 1:47 PM IST
      New Delhi : Morepen Laboratories Ltd. has reported a 60 per cent rise in its net profit for the first quarter (Q1) of FY 2016-17. The net profit...
      Lilly breast cancer drug stumbles, but trial continues

      Lilly breast cancer drug stumbles, but trial continues

      savita thakur thakur11 Aug 2016 1:47 PM IST
      U.S. drugmaker Eli Lilly and Co said it would continue a late stage trial of its experimental breast cancer drug in combination with a widely used...
      Claris to Start Sale of $500 Million US Injectables Unit

      Claris to Start Sale of $500 Million US Injectables Unit

      savita thakur thakur11 Aug 2016 1:47 PM IST
      Indian pharmaceutical producer Claris Lifesciences Ltd. has started a sale of its U.S. injectable drug business, which could fetch at least $500...
      FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

      FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

      savita thakur thakur11 Aug 2016 1:03 PM IST
      Kenilworth : Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved...
      Indian Medical Devices soon in government hospitals

      Indian Medical Devices soon in government hospitals

      savita thakur thakur10 Aug 2016 1:24 PM IST
      In a move to provide push to Indian device Manufacturers, as a part of PM Modi's Make in India Campaign, the central government is reported to have...
      Eisai: FDA confirms enough data to move Alzheimers drug to Phase III studies

      Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies

      savita thakur thakur10 Aug 2016 11:54 AM IST
      Japan's Eisai Co said the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok